Panacea Pharmaceuticals, a clinical stage bio-pharmaceutical company developing novel biologically–targeted cancer therapies and diagnostics declared the enrollment of patient in an open-label, parallel-designed, multi-center Phase 1 clinical trial of PAN-301-1 for the treatment of persistent prostate cancer .
PAN-301-1 is a novel nanoparticle immunotherapy vaccine candidate targeting human aspartyl (asparaginyl) β-hydroxylase (HAAH) also known as aspartate β-hydroxylase (ASPH). In the Phase 1 trial, PAN-301-1 is being administered via intradermal injection in patients with biochemically relapsed prostate cancer, using a fixed dose-escalation schema every 21 days to establish the recommended Phase 2 dose.
Hossein A. Ghanbari, Ph.D., President, Chief Executive Officer and Chief Science Officer, Panacea Pharmaceuticals claimed “We are extremely pleased by the rapid progress of our first clinical study of PAN-301-1. The Phase 1 study results reinforce our belief that we have created a safe and promising new therapeutic cancer vaccine candidate targeting a specific cancer-relevant marker and overcoming self-tolerance, yet avoiding the serious side effects associated with many other immunotherapeutic cancer drugs.”
Twelve patients have been enrolled. A minimum of 3 doses of vaccine are administered to each subject. Based on this announced completion of study enrollment, the trial will end in the first half of 2018.